Physician profile
Georgia Lea
NPI 1558574897
$625.82
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $516 · 2020: $109.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $182.46 | 2019 | |
| Boston Scientific Corporation | $156.12 | 2019-2020 | |
| Acorda Therapeutics, INC | $69.35 | 2019-2020 | |
| Mdd US Operations, LLC | $36.58 | 2019 | |
| Acadia Pharmaceuticals INC | $34.25 | 2019 | |
| Medtronic USA, INC. | $27.66 | 2020 | |
| Kyowa Kirin, INC. | $26.10 | 2020 | |
| Allergan, INC. | $22.71 | 2020 | |
| Adamas Pharmaceuticals, INC. | $17.43 | 2019 | |
| Amgen INC. | $13.82 | 2019 | |
| Ucb, INC. | $13.31 | 2019 | |
| Neurocrine Biosciences, INC. | $13.07 | 2019 | |
| Portola Pharmaceuticals, LLC | $12.96 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Georgia Lea listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.